low-titer O-group whole blood
Phase 3Small molecule
low-titer O-group whole blood is one of 14 small molecule programs targeting Blood Transfusion. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Blood Transfusion
#DrugCompanyPhaseTrials
1Cyklokapron
AAmring
Approved
Desferal
Alnylam PharmaceuticalsPhase 3
Ferinject
VVifor Pharma
Approved
Exjade
NovartisPhase 2
ICL670
NovartisPhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
low-titer O-group whole blood
XXijing Hospital
Phase 3
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 1
Umbilical Cord Blood Unit
WWeill Medical College of Cornell University
Phase 2
ASD CB-MNC Injection.
SState-Financed Health Facility "Samara Regional Medical Center Dinasty"
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- XXijing Hospital